Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

BRI Oppty in Crohns / IBD

BRI MOA as both PDE4 and antibacterial make for stronger potential in treating fuller IBD

Deficient Defensins contributing to IBD pathogenesis, esp Crohns
- IBD more a barrier issue / impt of Mucosal healing... forte of Defensins

http://www.ipharminc.com/new-blog/2017/10/24/deficient-defensins-and-missing-mucins-in-the-pathogenesis-of-inflammatory-bowel-disease

Given unique and broad mechanisms of action, defensin-based therapeutics, of which Brilacidin is a leading example, increasingly are viewed as promising avenues for IBD drug development:

· “A promising approach is the development of novel drugs like defensin-derived molecules that substitute for the missing endogenous antibacterials.” (Source)

· “The potential for enteric defensins as tools of clinical intervention grows as our understanding of their role in host health and immunity increases.” (Source)

· “Knowledge about defensins and others antimicrobial peptides could have a substantial influence on future therapeutic strategies.” (Source, pdf)

——

“Crohn's Progression Unchanged Despite Advanced Therapies”

https://www.medscape.com/viewarticle/892718

http://gut.bmj.com/content/early/2018/01/23/gutjnl-2017-315568.long

Use of advanced therapies for Crohn's disease (CD) has not significantly altered the natural disease course and phenotypes compared with those reported before the era of biologic therapies, a recent study suggests.

"Despite an earlier and more aggressive treatment with immunomodulators and biological therapy, rates of surgery and disease progression were not significantly different from previous population-based inception cohorts 20 years ago," write Johan Burisch, MD, PhD, from North Zealand University Hospital, Frederikssund, Denmark, and colleagues.

-

Instead of merely treating to symptoms, Dr Hudesman stressed the need for more data examining the effects of treating to target; that is, healing of the mucosa.